S. Manaviazar et al. / Tetrahedron Letters 52 (2011) 2080–2084
2083
formed in which 13 predominated. Importantly, the purified 18:1
mixture enriched in 13 could be isolated in pure condition in
97% yield following SiO2 flash chromatography. As expected, io-
dine-tin exchange and Stille cross-coupling of 30 with Me4Sn and
Pd(0), both proceeded smoothly to deliver the desired trisubsti-
tuted olefin 12 in essentially pure condition in 75% yield over
two steps.
Ester 12 was now reduced to the primary alcohol with DIBAL-
H, and this product oxidized to aldehyde 31 with catalytic TEMPO
and excess iodobenzene diacetate, using the excellent procedure
of Piancatelli.14 Significantly, all of the other oxidants that were
examined in this reaction also caused an extensive, and highly
problematical, epimerization of the C(11)-methyl stereocentre
Concurrent with our development of this new pathway to al-
kyne 8, we also addressed the synthesis of epoxide 9 (Scheme 6).
Our new route repeated some of the excellent chemistry of Steven-
son18 for the acquisition of alkene 36. The latter had its Boc-group
replaced by an N-trifluoroacetamido-group in order to permit the
anchimerically-assisted stereoselective iodo-hydroxylation reac-
tion on 11; a reaction which proceeded in 87–89% yield and deliv-
ered 10 as the major component of a 11.7:1 mixture.11 Treatment
of the latter with excess 3 M aqueous NaOH in dioxane thereafter
simultaneously formed the terminal epoxide and cleaved the
N-trifluoroacetamido substituent to allow an in situ N-acylation
with benzyl chloroformate to obtain 9. Although this new route
to 9 is 3 steps longer than the previous Overman route it does,
nonetheless, proceed with high stereocontrol and, it does now fi-
nally overcome the previous requirement to use preparative HPLC
to continue the synthesis.
To summarise, we have completed a new and greatly improved
formal asymmetric total synthesis of (+)-pumiliotoxin B that inter-
sects with Overman’s elegant 1996 synthesis7b of this natural
product. Significantly our new route to his advanced intermediates
8 and 9 is 2 steps shorter than his second-generation path to this
target, and its major advantage resides in the fact that it is highly
stereocontrolled and it now removes the need to do preparative
HPLC to advance forward. By completing this new formal route,
we have demonstrated here, for the first time ever that our new
O-directed free radical hydrostannation process can be beneficially
and powerfully used to position an ornate trisubstituted olefin
within a complex natural product. Further applications of the O-di-
rected free radical hydrostannation process in the total synthesis of
other complex natural products will be reported in due course.
a- to the aldehydo group, and quite considerable oxidant screen-
ing was required before we eventually identified these optimal
oxidation conditions. Following SiO2 flash chromatography, alde-
hyde 31 was isolated in pure condition in 86% yield and it was
used directly for the subsequent Corey–Fuchs dibromolefination15
step without delay. The latter reaction was first applied on 31 by
Kibayashi8d in his total synthesis of allo-pumiliotoxin 339A. Dib-
romoalkene 32 also featured in Overman’s pathway to (+)-pumi-
liotoxin B and, in this context, 32 had previously been converted
into alkyne 8 by low temperature treatment with two equivalents
of n-BuLi in THF;7b both sets of chemistry were successfully re-
peated by us.
Although we did indeed attempt the direct alkynylation of alde-
hyde 31 with the Ohira–Bestmann reagent,16 the fairly basic
conditions under which this method operates proved totally
incompatible with preservation of the C(11)-Me stereochemistry
in 31. Whilst the reaction was itself chemically successful at deliv-
ering the alkynylated product 8 in high yield, it also led to a signif-
icant amount of terminal alkyne diastereomer at C(11), which
proved inseparable by SiO2 flash chromatography. Thus, this par-
ticular direct method for converting 31 into 8 was simply not via-
ble, making the lengthier two-step Corey–Fuchs alkynylation
pathway to 8 almost mandatory.17
Acknowledgements
We thank Novartis Pharma AG, the ACS and Queen’s University
Belfast for financial support. We thank Dr. Paul Stevenson (QUB)
for helpful advice on the preparation of 36.
Supplementary data
(i) Et N (2 eq), DMF,
3
0 ºC, 45 min, filter
off salt, cool filtrate
(ii) MeMgI (3M in Et O)
2
Supplementary data (copies of the 400 and 500 MHz 1H and
125 MHz 13C NMR spectra are supplied for all the new and previ-
ously unreported intermediates described in this route) associated
with this article can be found, in the online version, at doi:10.1016/
NH Cl
2
NBoc
NBoc
H
(3 eq), Et O, 0 ºC, then
2
OH
Me
warm to rt, 6 h
(87%, 2 steps)
CO Me
CO Me
2
to 0ºC, add Boc
O
2
2
H
H
(1.1 eq) in DMF over
20 min, warm to rt,
stir, 19 h
Me
35
33
34
(iii) To 35 in THF,
CF
at -78 ºC, add
3
(iv) CF CO H (10 eq),
3
2
SOCl (2.1 eq),
2
References and notes
NBoc
N
H
O
CH Cl , rt, 2 h
2
2
stir 2.5 h, then add
Et N (17 eq) dropwise,
stir at -78 ºC, 2 h, and
warm to rt (62%)
(v) (CF CO) O (4 eq),
3
1. Dimopoulos, P.; Athlan, A.; Manaviazar, S.; George, J.; Walters, M.; Lazarides, L.;
Aliev, A. E.; Hale, K. J. Org. Lett. 2005, 7, 5369–5372.
2. Dimopoulos, P.; Athlan, A.; Manaviazar, S.; Hale, K. J. Org. Lett. 2005, 7, 5373–
5376.
3
2
H
Me
Me
Et N (8 eq), CH Cl ,
3
2
2
11
36
rt, 16 h (87%)
3. For our detailed investigations into the mechanism of the O-directed
alkylacetylene hydrostannation, see: Dimopoulos, P.; George, J.; Manaviazar,
S.; Tocher, D. A.; Hale, K. J. Org. Lett. 2005, 7, 5377–5380.
4. For an account of our attempts to use this stannation method in the synthesis
of the A83586C/kettapeptin pyran side-chain, see: Hale, K. J.; Manaviazar, S.;
George, J. Chem. Commun. 2010, 46, 4021–4042.
CF
3
(vii) 3M aq. NaOH
(20 eq), 1,4-
NZ
(vi) NIS (2 eq), THF:H O
2
N
H
O
dioxane, rt, 0.5 h,
(50:1), -20 ºC , 1.5 h,
then rt, 16 h (87-89%)
I
then add
H
O
OH
Me
10
Me
9
ZCl (1 eq), 4.5 h
(64%)
5. See: Handbook of Organopalladium Chemistry for Organic Synthesis; Negishi, E.,
Ed.; Wiley-Interscience: New York, 2002; Vols. 1–2,.
+
6. Daly, J. W.; Myers, C. W. Science (Washington D.D.) 1967, 156, 970–973.
7. For previous (+)-pumiliotoxin B total syntheses, see: (a) Overman, L. E.; Bell, K.
L.; Ito, F. J. Am. Chem. Soc. 1984, 4192–4201; (b) Lin, N.-H.; Overman, L. E.;
Rabinowitz, M. H.; Robinson, L. A.; Sharp, M. J.; Zablocki, J. J. Am. Chem. Soc.
1996, 118, 9062–9072; (c) Kibayashi, C.; Aoyagi, S. J. Organomet. Chem. 2002,
653, 229–233; (d) Aoyagi, S.; Hirashima, S.; Saito, K.; Kibayashi, C. J. Org. Chem.
2002, 67, 5517–5526; For a review on pumiliotoxin alkaloid synthesis, see: (e)
Franklin, A.; Overman, L. E. Chem. Rev. 1996, 96, 505–522.
Me OH
Me
L.E. Overman
et al.
Me Me
Me
Me
O
OH
N
H
O
Me
Me
Reference 7 b
8
OH
Me
8. For recent syntheses of the structurally related allo-pumiliotoxins, see: (a)
Overman, L. E.; Goldstein, S. W. J. Am. Chem. Soc. 1984, 106, 5360–5361; (b)
Goldstein, S. W.; Overman, L. E.; Rabinowitz, M. H. J. Org. Chem. 1992, 57, 1179–
1190; (c) Trost, B. M.; Scanlan, T. S. J. Am. Chem. Soc. 1989, 111, 4988–4990; (d)
(+)-Pumiliotoxin B
Scheme 6. The final stages of our new formal total synthesis of (+)-pumiliotoxin B.